MoneyWorks4Me

Check Before You Invest : Biogen Pharmachem Industries Ltd

BSE: 531752 NSE: ISIN: INE703D01023
  |   Sector:  Miscellaneous   |   Industry:  Trading

Snapshot

Q.1 Which industry/sub-sector does Biogen Pharmachem Industries Ltd belong to?
Biogen Pharmachem Industries Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.
Q.2 Is Biogen Pharmachem Industries Ltd a good quality company?
Biogen Pharmachem Industries Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Biogen Pharmachem Industries Ltd undervalued or overvalued?
Biogen Pharmachem Industries Ltd appears Fair, as its key valuation ratios are in line with their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios Current 0-year
Historic Median
Price to Earnings - -
Price to Book - -0.17
Price to Sales - -
EV to EBITDA - 1225.01
Q.4 Is Biogen Pharmachem Industries Ltd a good buy now?
Biogen Pharmachem Industries Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

C: How much debt does the business have and is it at a sustainable level?

Q.1 Debt to Equity ratio of Biogen Pharmachem Industries Ltd?
Biogen Pharmachem Industries Ltd Debt-to-Equity ratio is 0.00, which is in line with the industry average of , indicating similar to debt levels in the industry.

Q.2 Debt to cash flow from operations of Biogen Pharmachem Industries Ltd?
Biogen Pharmachem Industries Ltd Debt to cash flow from operations is 0, which is at a healthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Biogen Pharmachem Industries Ltd?

Q.1 Promoter shareholding and pledge status of Biogen Pharmachem Industries Ltd?
Promoters hold 0.00% of the Biogen Pharmachem Industries Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Biogen Pharmachem Industries Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Biogen Pharmachem Industries Ltd vs industry peers?
Biogen Pharmachem Industries Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Profit Metrics
Current Level 0-year
Industry Median
Revenue Growth (%) - -
Gross Profit Growth (%) - 14.9
Operating Profit Growth (%) - 15.3
Net Profit Growth (%) - 15.7
Operating Efficiency
Current Level 0-year
Industry Median
Asset Turnover (x) - 0.48
ROE (%) - 4.89
ROCE (%) - 7.53
Cash Conversion Cycle (days) - 37

Valuation & price assessment

Q.1 Stock return of Biogen Pharmachem Industries Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 4.5% based on the current price.
9Y 5Y 3Y 1Y
Share Price
CAGR
4.5% -12% -26% -62.2%
Q.2 Valuation ratios of Biogen Pharmachem Industries Ltd vs historical?
The current P/E ratio of 0 is in line with than its historical median of , indicating that the stock is trading near its historical average valuation.
Q.3 How do the current valuation ratios compare with 0-year historical median and industry numbers?
Valuation Ratios Current 0-year
Historic Median
0-year
Industry Median
Price to Earnings - - -
Price to Book - -0.17 -
Price to Sales - - -
EV to EBITDA - 1225.01 -

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: